一项评估 AZD2389 在肝纤维化和代偿性肝硬化参与者中的安全性、耐受性、PK 和 PD 效应的研究。 (BORANA)
一项 2a 期、随机、单盲、安慰剂对照研究,旨在评估 AZD2389 对肝纤维化和代偿性肝硬化受试者的安全性、耐受性和药代动力学,并探索其药效学作用
研究概览
详细说明
研究细节包括:
研究持续时间最长为63天(9周)。
- 1 或 2 次筛查访视(治疗前最多 28 天)
- 28 天的治疗,包括 5 次就诊
- 第 1 周:24 小时在诊所停留(第 1 天)
- 第 2 周:门诊就诊(第 7 天)
- 第 3 周:门诊就诊(第 14 天)
- 第 4 周:电话拜访(第 21 天)
- 第 5 周:在诊所停留 24 至 48 小时(第 28 天)
- 第 6 周:随访(第 35 天) 披露声明:该研究由两个队列组成,每个队列均采用平行组设计和两个组,参与者对治疗分配不知情。
参加人数:
该研究总共将随机分配约 36 名参与者。 A 组:将对大约 75 名疑似患有 MASH/NASH 并伴有纤维化的参与者进行筛查,其中大约 18 名参与者将被随机分配。 12 名参与者将随机接受 AZD2389,6 名参与者将接受安慰剂。 B 组:将对约 75 名患有晚期纤维化(包括代偿性肝硬化)的 SLD 参与者进行筛查,其中约 18 名参与者将被随机分配。 12 名参与者将随机接受 AZD2389,6 名参与者将接受安慰剂。
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
San Juan、波多黎各、00927
- Research Site
-
-
-
-
Arizona
-
Chandler、Arizona、美国、85224
- Research Site
-
-
California
-
Rialto、California、美国、92377
- Research Site
-
-
Georgia
-
Atlanta、Georgia、美国、30349
- Research Site
-
-
North Carolina
-
Morehead City、North Carolina、美国、28557
- Research Site
-
-
Texas
-
Houston、Texas、美国、77079
- Research Site
-
San Antonio、Texas、美国、78229
- Research Site
-
San Antonio、Texas、美国、78215
- Research Site
-
-
-
-
-
Cambridge、英国、CB2 0QQ
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
主要内容:
- 年龄≥18岁的男性/女性
- 适应症:推测患有 MASH(A 组)或其他伴有纤维化的脂肪肝病(B 组)
- 过去 6 个月体重无明显变化
- 男性使用屏障避孕药
- 能够获得知情同意
- 经研究者判定适合研究
主要排除:
- 可能使参与者面临风险、影响参与者参与试验的能力、干扰研究干预评估或影响结果解释的情况
- 肝病的其他原因并非每个队列的主要纳入标准
- 肝脏血液检查或血小板显着升高<140 x10^9/L
- 失代偿性肝病、肝胆癌或肝移植清单
- 出血性疾病或大出血风险
- HIV感染或乙型肝炎感染
- 具有临床意义的心血管疾病(例如 过去3个月内患有严重缺血性心脏病、严重心力衰竭或心律失常)或脑血管疾病
- 2期高血压
- eGFR <60ml/min/1.73m2
- 具有临床意义的胃肠道疾病,可能影响药代动力学、安全性和耐受性数据的解释
- 皮肤疾病或正在进行的伤口愈合
- 可能对参与试验产生负面影响的精神疾病。
- 有生育能力的女性
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:A组
将对疑似患有纤维化的 MASH/NASH 的参与者进行筛查,以便将大约 18 名参与者进行随机分组。
12 名参与者将随机接受 AZD2389,6 名参与者将接受安慰剂。
|
AZD2389 或安慰剂的剂量将口服给药。
|
|
其他:B组
患有晚期纤维化(包括代偿性肝硬化)的 SLD 参与者将接受筛查,大约 18 名参与者将被随机分配。
12 名参与者将随机接受 AZD2389,6 名参与者将接受安慰剂。
|
AZD2389 或安慰剂的剂量将口服给药。
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Notable Trends in Laboratory Assessments (Haematology, Coagulation, Clinical Chemistry, Fibrinolysis, and Urinalysis)
大体时间:From screening up to and including Day 35
|
The number of participants with notable trends in laboratory assessments (haematology, coagulation, clinical chemistry, fibrinolysis, and urinalysis) is presented. Notable trends were assessed based on evaluation of mean values over time, individual participant values, and clinically important abnormalities, including values outside predefined criteria. |
From screening up to and including Day 35
|
|
Clinically Relevant Trends in Vital Signs (Blood Pressure, Pulse Rate, Oxygen Saturation, Body Temperature, and Respiration Rate), and 12-lead Electrocardiogram (ECG)
大体时间:From Screening up to and including Day 35
|
The number of participants with clinically relevant trends in vital signs (blood pressure, pulse rate, oxygen saturation, body temperature, and respiration rate), and12-lead ECGs is presented. Clinically relevant trends were assessed based on trends or group changes over time, changes in individual participants over time, and individual clinically important abnormalities. |
From Screening up to and including Day 35
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Cmax
大体时间:Day 1 and Day 28
|
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Cmax= Maximum Concentration |
Day 1 and Day 28
|
|
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Tmax
大体时间:Day 1 and Day 28
|
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. tmax = Time to Maximum Concentration |
Day 1 and Day 28
|
|
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: t1/2 Lambda z
大体时间:Day 1 and Day 28
|
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. t1/2 lambda z= Apparent Terminal Half-life |
Day 1 and Day 28
|
|
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: AUClast, AUCinf, and AUCtau
大体时间:Day 1 and Day 28
|
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. AUClast= Area Under the Concentration-time Curve to the Last Measurable Concentration AUCinf = Area Under the Concentration-time Curve Extrapolated to Infinity AUCtau = Area Under the Concentration-time Curve Over a Dosing Interval AUCtau presented as AUC(0-24h) in the table. In line with standard PK analysis methodologies, AUCinf was estimated only for Day 1. AUClast and AUCtau were estimated for both Day 1 and Day 28. |
Day 1 and Day 28
|
|
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Lambda z
大体时间:Day 1 and Day 28
|
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. lambda z = Terminal elimination rate constant |
Day 1 and Day 28
|
|
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Vz/F
大体时间:Day 1 and Day 28
|
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Vz/F = Apparent Volume of Distribution |
Day 1 and Day 28
|
|
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: CL/F and CLR
大体时间:Day 1 and Day 28
|
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. CL/F = Apparent Clearance CLR = Renal Clearance |
Day 1 and Day 28
|
|
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: TCP AUC
大体时间:Day 28
|
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. TCP is calculated as the ratio of steady-state AUCtau (AUC0-24h) to first-dose AUCinf TCP = Temporal Change Parameter AUC = Area Under the Concentration-time Curve |
Day 28
|
|
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Rac AUC and Rac Cmax
大体时间:Day 28
|
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Rac AUC = AUC Accumulation Ratio; ratio of steady state AUCtau (AUC0-24h)/First Dose AUCtau (AUC0-24h) Rac Cmax = Cmax Accumulation Ratio; ratio of steady state Cmax/First Dose Cmax |
Day 28
|
|
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Ae (0-24)
大体时间:Day 1 and Day 28
|
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Ae (0-24) = Cumulative Amount of Drug Excreted Unchanged in Urine |
Day 1 and Day 28
|
|
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Fe (0-24)
大体时间:Day 1 and Day 28
|
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Fe = Fraction of Dose Excreted Unchanged into Urine |
Day 1 and Day 28
|
|
Inhibition of FAP Activity Calculated as Percentage Change in FAP Activity Against Baseline Compared to Placebo.
大体时间:Day 28
|
Effect of AZD2389 on plasma FAP activity following oral administration of AZD2389 in participants with chronic Liver Disease and hepatic fibrosis was evaluated and presented as percentage change from baseline in FAP activity. Percentage change when comparing post-treatment visits to baseline for each group, calculated as (Geometric LS mean - 1) *100. FAP=Fibroblast Activating Protein |
Day 28
|
合作者和调查者
赞助
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
合格的研究人员可以通过请求门户 Vivli.org 请求访问阿斯利康集团公司赞助的临床试验的匿名个人患者级别数据。 所有请求都将根据 AZ 披露承诺进行评估:https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure。
是的,表示AZ正在接受IPD请求,但这并不意味着所有请求都会被共享。
IPD 共享时间框架
IPD 共享访问标准
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.